Literature DB >> 24028267

Prevalence of HCV infection among clients in community-based health settings in Hawaii, 2002-2010: assessing risk factors.

Jeremy C Porter1, Heather M Lusk, Alan R Katz.   

Abstract

OBJECTIVES: We sought to determine the prevalence of HCV infection and identify risk factors associated with HCV infection among at-risk clients presenting to community-based health settings in Hawaii.
METHODS: Clients from 23 community-based sites were administered risk factor questionnaires and screened for HCV antibodies from December 2002 through May 2010. We performed univariate and multivariate logistic regression analyses.
RESULTS: Of 3306 participants included in the analysis, 390 (11.8%) tested antibody positive for HCV. Highest HCV antibody prevalence (17.0%) was in persons 45 to 64 years old compared with all other age groups. Significant independent risk factors were current or prior injection drug use (P < .001), blood transfusion prior to July 1992 (P = .002), and having an HCV-infected sex partner (P = .03). Stratification by gender revealed sexual exposure to be significant for males (P = .001).
CONCLUSIONS: Despite Hawaii's ethnic diversity, high hepatocellular carcinoma incidence, and a statewide syringe exchange program in place since the early 1990s, our HCV prevalence and risk factor findings are remarkably consistent with those reported from the mainland United States. Hence, effective interventions identified from US mainland population studies should be generalizable to Hawaii.

Entities:  

Mesh:

Year:  2013        PMID: 24028267      PMCID: PMC4103216          DOI: 10.2105/AJPH.2013.301282

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  30 in total

1.  Hepatocellular cancer: risk factors and survival in Pacific Islanders compared to Caucasians in Hawaii.

Authors:  Margaret Ochner; Linda L Wong; Kristal Wimmer-Kunitomo
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

Review 2.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

Authors:  J M Micallef; J M Kaldor; G J Dore
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

3.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

Authors:  Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-11       Impact factor: 11.382

4.  Hepatitis C virus infection in a human immunodeficiency virus-positive cohort in Hawaii.

Authors:  R L Vogt; S Richmond-Crum; A Diwan
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

5.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

6.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

7.  Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal.

Authors:  Alan Neaigus; Mingfang Zhao; V Anna Gyarmathy; Linda Cisek; Samuel R Friedman; Robert C Baxter
Journal:  J Urban Health       Date:  2008-03-14       Impact factor: 3.671

Review 8.  NIH Consensus Statement on Management of Hepatitis C: 2002.

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Jun 10-12

9.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

View more
  4 in total

1.  Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study.

Authors:  Sabrina A Assoumou; Shayla Nolen; Liesl Hagan; Jianing Wang; Golnaz Eftekhari Yazdi; William W Thompson; Kenneth H Mayer; Jon Puro; Lin Zhu; Joshua A Salomon; Benjamin P Linas
Journal:  Am J Med       Date:  2020-06-27       Impact factor: 4.965

2.  Hepatitis C virus antibody prevalence, demographics and associated factors among persons screened at Hawai'i community-based health settings, 2010-2013.

Authors:  Lisa C Takeuchi; Thaddeus K Pham; Alan R Katz
Journal:  Hawaii J Med Public Health       Date:  2015-01

3.  Impact of Social Determinants of Health on Medical Conditions Among Transgender Veterans.

Authors:  John R Blosnich; Mary C Marsiglio; Melissa E Dichter; Shasha Gao; Adam J Gordon; Jillian C Shipherd; Michael R Kauth; George R Brown; Michael J Fine
Journal:  Am J Prev Med       Date:  2017-02-01       Impact factor: 5.043

4.  Hepatitis B Core Antibody Positivity Associated with Increased Risk of Liver Cancer in Patients with Chronic Hepatitis C: Analysis of a Large Patient Cohort in Hawai'i.

Authors:  Olivia A Collis; Patrycja A Ashley; Li-Hsieh Chen; Kathryn L Pedula; Shelley M Miyashiro; Shellie K Yamashita
Journal:  Hawaii J Health Soc Welf       Date:  2022-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.